Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

This problem has a solution, and Pfizer is implementing it.

CryptoAlerta — análise de criptomoedas e mercado em tempo real